SAB Biotherapeutics (SABS) Competitors $2.00 -0.18 (-8.26%) Closing price 03:59 PM EasternExtended Trading$2.03 +0.03 (+1.50%) As of 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SABS vs. ACHV, DOMH, FBIO, CRIS, BOLT, AMGN, GILD, VRTX, REGN, and ALNYShould you be buying SAB Biotherapeutics stock or one of its competitors? The main competitors of SAB Biotherapeutics include Achieve Life Sciences (ACHV), Dominari (DOMH), Fortress Biotech (FBIO), Curis (CRIS), Bolt Biotherapeutics (BOLT), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Alnylam Pharmaceuticals (ALNY). These companies are all part of the "biotechnology" industry. SAB Biotherapeutics vs. Its Competitors Achieve Life Sciences Dominari Fortress Biotech Curis Bolt Biotherapeutics Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Achieve Life Sciences (NASDAQ:ACHV) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation. Which has more risk & volatility, ACHV or SABS? Achieve Life Sciences has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Does the media favor ACHV or SABS? In the previous week, SAB Biotherapeutics had 5 more articles in the media than Achieve Life Sciences. MarketBeat recorded 5 mentions for SAB Biotherapeutics and 0 mentions for Achieve Life Sciences. Achieve Life Sciences' average media sentiment score of 0.00 beat SAB Biotherapeutics' score of -0.80 indicating that Achieve Life Sciences is being referred to more favorably in the media. Company Overall Sentiment Achieve Life Sciences Neutral SAB Biotherapeutics Negative Do insiders and institutionals believe in ACHV or SABS? 33.5% of Achieve Life Sciences shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 3.0% of Achieve Life Sciences shares are owned by insiders. Comparatively, 27.8% of SAB Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts recommend ACHV or SABS? Achieve Life Sciences currently has a consensus price target of $16.00, indicating a potential upside of 522.57%. SAB Biotherapeutics has a consensus price target of $11.00, indicating a potential upside of 450.00%. Given Achieve Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Achieve Life Sciences is more favorable than SAB Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Achieve Life Sciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.67SAB Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings & valuation, ACHV or SABS? SAB Biotherapeutics has higher revenue and earnings than Achieve Life Sciences. Achieve Life Sciences is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAchieve Life SciencesN/AN/A-$39.83M-$1.46-1.76SAB Biotherapeutics$1.32M15.77-$34.10M-$4.00-0.50 Is ACHV or SABS more profitable? SAB Biotherapeutics' return on equity of -153.92% beat Achieve Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Achieve Life SciencesN/A -193.49% -116.68% SAB Biotherapeutics N/A -153.92%-89.16% SummarySAB Biotherapeutics beats Achieve Life Sciences on 8 of the 15 factors compared between the two stocks. Get SAB Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SABS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SABS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SABS vs. The Competition Export to ExcelMetricSAB BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.82M$3.06B$5.76B$9.65BDividend YieldN/A2.22%3.91%4.09%P/E Ratio-0.5020.6130.7825.12Price / Sales15.77358.53457.76157.42Price / CashN/A41.5625.2228.45Price / Book0.719.509.365.94Net Income-$34.10M-$54.72M$3.26B$265.56M7 Day Performance-7.41%2.39%1.83%0.95%1 Month Performance-22.18%4.60%3.69%2.47%1 Year Performance-27.80%9.11%28.88%20.24% SAB Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SABSSAB Biotherapeutics2.687 of 5 stars$2.00-8.3%$11.00+450.0%-10.1%$20.82M$1.32M-0.50140ACHVAchieve Life Sciences1.5832 of 5 stars$2.44-2.5%$14.33+488.2%-40.9%$86.71MN/A-1.6820DOMHDominari1.0087 of 5 stars$5.33-7.0%N/A+313.3%$83.91M$18.15M-1.184News CoverageAnalyst UpgradeFBIOFortress Biotech2.528 of 5 stars$1.92+5.5%$21.00+993.8%+21.0%$53.82M$57.67M-0.86170Earnings ReportCRISCuris3.0829 of 5 stars$1.69-1.2%$17.00+906.5%-58.6%$21.37M$10.91M-0.3360Positive NewsBOLTBolt Biotherapeutics2.9564 of 5 stars$5.52-0.9%$50.00+805.8%-63.5%$10.68M$7.69M-0.1790News CoverageEarnings ReportAMGNAmgen4.6679 of 5 stars$285.79-0.8%$303.76+6.3%-9.0%$155.17B$33.42B23.3728,000Positive NewsGILDGilead Sciences4.9652 of 5 stars$120.41+0.8%$114.82-4.6%+59.9%$148.16B$28.75B24.0017,600Positive NewsAnalyst UpgradeInsider TradeVRTXVertex Pharmaceuticals4.9324 of 5 stars$374.46+2.2%$497.10+32.8%-18.3%$93.98B$11.02B26.776,100Positive NewsREGNRegeneron Pharmaceuticals4.8713 of 5 stars$550.03-2.3%$826.91+50.3%-51.3%$59.67B$14.20B13.7615,106Positive NewsDividend AnnouncementALNYAlnylam Pharmaceuticals4.1507 of 5 stars$435.94-0.7%$403.92-7.3%+70.3%$57.53B$2.25B-176.112,230Trending NewsInsider Trade Related Companies and Tools Related Companies ACHV Competitors DOMH Competitors FBIO Competitors CRIS Competitors BOLT Competitors AMGN Competitors GILD Competitors VRTX Competitors REGN Competitors ALNY Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SABS) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SAB Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access